Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by abrdn plc

abrdn plc increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the fourth quarter, Holdings Channel reports. The firm owned 188,451 shares of the biopharmaceutical company’s stock after buying an additional 1,740 shares during the quarter. abrdn plc’s holdings in Regeneron Pharmaceuticals were worth $133,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in REGN. Centaurus Financial Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $118,000. Czech National Bank increased its holdings in Regeneron Pharmaceuticals by 7.0% during the 3rd quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock valued at $22,725,000 after acquiring an additional 1,405 shares in the last quarter. Park Avenue Securities LLC increased its holdings in Regeneron Pharmaceuticals by 7.6% during the 3rd quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 134 shares in the last quarter. GAMMA Investing LLC increased its holdings in Regeneron Pharmaceuticals by 32.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock valued at $1,510,000 after acquiring an additional 353 shares in the last quarter. Finally, Miracle Mile Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 12.6% during the 3rd quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $2,693,000 after acquiring an additional 286 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on REGN. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ:REGN opened at $666.85 on Tuesday. The company’s fifty day moving average is $720.81 and its two-hundred day moving average is $921.72. The stock has a market capitalization of $73.28 billion, a price-to-earnings ratio of 16.50, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1-year low of $663.43 and a 1-year high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.